Phase II Study of Daily Adaptive Radiotherapy for Submandibular Gland-sparing in Head and Neck Ca… (NCT07348887) | Clinical Trial Compass
RecruitingNot Applicable
Phase II Study of Daily Adaptive Radiotherapy for Submandibular Gland-sparing in Head and Neck Cancer
Canada50 participantsStarted 2025-10-15
Plain-language summary
This is a randomized, single centre, single blinded prospective study comparing the standard of care imaging guided radiation therapy and daily adaptive radiotherapy (ART) for submandibular gland-sparing in head and neck cancer
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years
* Histologically proven Squamous Cell carcinoma of head and neck
* Bilateral neck being treated
* At least one level 1b not being treated electively and with no target structure, other than elective level II/III, \<1cm to spared SMG
* ECOG PS 0-2
* Planned for curative (chemo)radiotherapy
* Able to receive and understand verbal and written information regarding study and able to give written informed consent
* Be able to lie comfortably on back and to wear immobilization for up to 1 hour
Exclusion Criteria:
* As judged by investigator evidence of systemic disease that makes unsuitable for study
* Pregnancy
* Underlying salivary dysfunction prior to treatment judged by investigator to affect likelihood of benefit from ART